Oral iron chelator L1 and autoimmunity [letter; comment]
نویسندگان
چکیده
منابع مشابه
Oral iron chelator L1 and autoimmunity.
As Brittenham’ has reviewed in detail, the use of the oral iron chelator LI has been associated with significant clinical and animal toxicity. One of the more controversial issues surrounding the human use of LI has been the possible development of autoimmune phenomena as manifested by development of autoantibodies such as antinuclear antibodies (ANA). The Canadian group investigating LI did no...
متن کاملEfficacy and Possible Adverse Effects of the Oral Iron Chelator
Eleven patients with p thalassemia major were entered into the trial of the oral chelator 1.2-dimethyl-3-hydroxypyrid-4one (L1). Their ages ranged from 17 to 26 years (mean & SD, 22.3 & 2.7). Six were male and five were female. L1 was administered at an initial daily dose of 42.5 to 60 mg/kg as a single dose. After 4 weeks, the dose was increased to 85 to 119 (102 f 10.7) mg/kg for 191 to 352 d...
متن کاملThe iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells.
Iron-mediated carcinogenesis is thought to occur through the generation of oxygen radicals. Iron chelators are used in attempts to prevent the long term consequences of iron overload. In particular, 1,2-dimethyl-3-hydroxypyrid-4-one (L1), has shown promise as an effective chelator. Using an established hepatocellular model of iron overload, we studied the generation of iron-catalyzed oxidative ...
متن کاملEfficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
Eleven patients with beta thalassemia major were entered into the trial of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Their ages ranged from 17 to 26 years (mean +/- SD, 22.3 +/- 2.7). Six were male and five were female. L1 was administered at an initial daily dose of 42.5 to 60 mg/kg as a single dose. After 4 weeks, the dose was increased to 85 to 119 (102 +/- 10.7) mg/kg for 19...
متن کاملIron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Several life-threatening complications of the common disorder sickle cell disease require management with red blood cell transfusions and, hence, long-term iron-chelating therapy. The efficacy of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) has not previously been determined in patients with sickle cell disease. We compared the efficacy of L1 to that of standard-dose subcutaneo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 1993
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v81.7.1970.1970